Kochański Andrzej
Zespół Badawczo-Leczniczy Chorób Nerwowo-Mieśniowych, Instytut Medycyny Doświadczalnej i Klinicznej im. M. Mossakowskiego, Polska Akademia Nauk, ul. Pawińskiego 5, 02-106 Warszawa, Poland.
Med Wieku Rozwoj. 2006 Jan-Mar;10(1 Pt 2):335-41.
The classification of amino-acid substitutions into pathogenic mutations and harmless polymorphisms should be revised. In the recent years it was shown that some amino-acid substitutions considered as pathogenic mutations were polymorphisms. Similarly, some 'harmless' polymorphisms have been shown to be pathogenic mutations. Functional analysis considered as a good method to estimate the pathogenic nature of mutations is also limited. The selection of DNA samples for the control group is also difficult. Due to the molecular mechanism mediated by recently discovered exonic splicing enhancers and silencers (ESE and ESS) it is hard to predict a pathogenic effect of some mutations. In addition, the phenotype variability observed between unrelated patients harboring the same mutation may reflect the effects of modifying genes as well as the lack of association between mutation and "its" phenotype. The aim of this study is to describe the problem of the pathogenic effect of mutations.
氨基酸替换分为致病突变和无害多态性的分类应予以修订。近年来已表明,一些被视为致病突变的氨基酸替换其实是多态性。同样,一些“无害”的多态性已被证明是致病突变。被认为是评估突变致病性质的好方法的功能分析也有局限性。为对照组选择DNA样本也很困难。由于最近发现的外显子剪接增强子和沉默子(ESE和ESS)介导的分子机制,很难预测某些突变的致病效应。此外,在携带相同突变的无关患者之间观察到的表型变异性可能反映了修饰基因的作用以及突变与“其”表型之间缺乏关联。本研究的目的是描述突变致病效应的问题。